1
|
Maraldo M, Giusti F, van der Kaaij M, Henry-Amar M, Aleman B, Raemaekers J, Meijnders P, Moser E, Kluin-Nelemans H, Spina M, Ferme C, Fortpied C, Specht L. Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-Up Study. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Petry S, Sévin C, Fleury MA, Duquesne F, Foucher N, Laugier C, Henry-Amar M, Tapprest J. Differential distribution of vapA-positive Rhodococcus equi in affected and unaffected horse-breeding farms. Vet Rec 2017. [PMID: 28642343 DOI: 10.1136/vr.104088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- S Petry
- ANSES, Dozulé Laboratory for Equine Diseases, Bacteriology and Parasitology Unit, Goustranville 14430, France
| | - C Sévin
- ANSES, Dozulé Laboratory for Equine Diseases, Epidemiology and Pathology Unit, Goustranville 14430, France
| | - M A Fleury
- ANSES, Dozulé Laboratory for Equine Diseases, Bacteriology and Parasitology Unit, Goustranville 14430, France
| | - F Duquesne
- ANSES, Dozulé Laboratory for Equine Diseases, Bacteriology and Parasitology Unit, Goustranville 14430, France
| | - N Foucher
- ANSES, Dozulé Laboratory for Equine Diseases, Bacteriology and Parasitology Unit, Goustranville 14430, France
| | - C Laugier
- ANSES, Dozulé Laboratory for Equine Diseases, Goustranville 14430, France
| | - M Henry-Amar
- Centre de lutte contre le cancer François Baclesse, Avenue du Général Harris, Caen cedex 5, 14076, France
| | - J Tapprest
- ANSES, Dozulé Laboratory for Equine Diseases, Epidemiology and Pathology Unit, Goustranville 14430, France
| |
Collapse
|
3
|
Maraldo M, Giusti F, van der Kaaij M, Henry-Amar M, Aleman B, Raemaekers J, Meijnders P, Moser E, Kluin-Nelemans H, Spina M, Ferme C, Fortpied C, Specht L. CARDIAC DISEASE PREDICTION FOLLOWING HODGKIN LYMPHOMA: AN EORTC LYMPHOMA GROUP AND GELA FOLLOW-UP STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.V. Maraldo
- Department of Clinical Oncology; Rigshospitalet; Copenhagen Denmark
| | - F. Giusti
- Department of Statistics; EORTC Headquarters; Brussels Belgium
| | - M.A. van der Kaaij
- Department of Internal Medicine; VU University Medical Centre; Amsterdam Netherlands
| | - M. Henry-Amar
- Centre de Traitement des Données du Cancéropôle Nord-Ouest; Centre François Baclesse; Caen France
| | - B. Aleman
- Department of Radiation Oncology; the Netherlands Cancer Institute; Amsterdam Netherlands
| | - J. Raemaekers
- Department of Hematology; Radboud University Medical Center; Nijmegen Netherlands
| | - P. Meijnders
- Department of Radiation Oncology, Iridium Cancer Network; University of Antwerp; Antwerp Belgium
| | - E.C. Moser
- Department of Radiation Oncology; Champalimaud Cancer Centre; Lisbon Portugal
| | - H.C. Kluin-Nelemans
- Department of Hematology; University Medical Centre Groningen, University of Groningen; Groningen Netherlands
| | - M. Spina
- Division of Medical Oncology; National Cancer Institute; Aviano Italy
| | - C. Ferme
- Department of Hematology; Institut Gustave Roussy; Villejuif France
| | - C. Fortpied
- Department of Statistics; EORTC Headquarters; Brussels Belgium
| | - L. Specht
- Department of Clinical Oncology; Rigshospitalet; Copenhagen Denmark
| |
Collapse
|
4
|
Maraldo M, Giusti F, Vogelius I, Lundemann M, Bentzen S, Van der Kaaij M, Aleman B, Henry-Amar M, Meijnders P, Moser E, Fortpied C, Specht L. OC-0060: Cardiac risk prediction: Moving beyond a mean heart dose model? Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31309-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
van der Kaaij M, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser E, Allgeier A, Meulemans B, Lugtenburg P, Aleman B, Noordijk E, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Eghbali H, Brice P, Smit W, Sebban C, Doorduijn J, Roesink J, Gaillard I, Coiffier B, Lybeert M, Casasnovas O, André M, Raemaekers J, Henry-Amar M, Kluin-Nelemans J. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Hum Reprod 2013; 29:525-33. [DOI: 10.1093/humrep/det430] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Meijnders P, Carde P, Girinsky T, Kluin-Nelemans J, Henry-Amar M, Raemaekers J, Karrasch M, van der Maazen R. Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy. EJC Suppl 2012. [DOI: 10.1016/s1359-6349(12)70019-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Caravati-Jouvenceaux A, Launoy G, Klein D, Henry-Amar M, Abeilard E, Danzon A, Pozet A, Veiten M, Mercier M. 6017 POSTER DISCUSSION Quality of Life and Reintegration of Long-Term Survivors of Colorectal Cancer: a Population-Based Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71662-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
van der Kaaij MAE, Heutte N, Meijnders P, Raemaekers JMM, Abeilard-Lemoisson E, Allgeier A, Meulemans B, Simons AHM, Mounier N, Henry-Amar M, Kluin-Nelemans JC. Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Caravati Jouvenceaux A, Launoy G, Danzon A, Henry-Amar M, Velten M, Mercier M. Qualité de vie et réinsertion des patients considérés guéris d’un cancer colorectal : étude à partir de registres de population. Rev Epidemiol Sante Publique 2011. [DOI: 10.1016/j.respe.2011.02.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
10
|
Joly F, Weber B, Pautier P, Fabbro M, Selle F, Krieger S, Leconte A, Bourgeois H, Henry-Amar M. Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC phase II trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5555] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5555 Background: High HER1 expression is associated with poor prognosis. Preliminary data have shown links between HER1 expression and topotecan efficacy. The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in non-HER screened patients who failed first line platinum-based chemotherapy within 12 months. Methods: Chemotherapy consisted of 4-week course of topotecan (d1, d8, d15, 3.2 mg/m2 IV) and lapatinib (1250 mg/d PO). Response was assessed using RECIST or RUSTIN criteria. The primary objective was global response (GR, i.e. CR, PR, and SD). Biomarker profiles were evaluated according treatment response. A two-step phase II trial was designed to include 54 patients assuming a GR rate of 75% for the combination compared to 55% for topotecan alone. Results: From March to September 2008, 39 patients (37 ovarian and 2 peritoneal carcinomas), median age 60 (18 to 80), were included in 16 institutions. Patients presented with FIGO stage I (n = 1), II (n = 2), III (n = 29), and IV (n = 7) disease. Twenty and 19 patients had disease relapse occurring < 6 and 6–12 months after initial chemotherapy respectively. 2 patients were non evaluable. After 1 to 8 cycles (median 2) of topotecan-lapatinib there were 0/2 PR, 7/9 SD, 12/7 progressions in patients who failed <6 or 6–12 months respectively. The GR rate was 46% (35 and 58%; 95% confidence limits, 30–63%) and the trial was prematurely stopped. Three patients developed toxicity leading to treatment discontinuation after 3 cycles. Biological data will be presented at meeting. Conclusions: Combined topotecan and lapatinib is associated with modest GR rate. Biological profiles of responders are pending. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Joly
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - B. Weber
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - P. Pautier
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - M. Fabbro
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - F. Selle
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - S. Krieger
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - A. Leconte
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - H. Bourgeois
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| | - M. Henry-Amar
- Centre François Baclesse, Caen, France; Centre Alexis Vautrin, Nancy, France; Institut Gustave Roussy, Villejuif, France; Centre Val d'Aurelle, Montpellier, France; AP-HP, Hôpital Tenon, Paris, France; Centre Jean Bernard, Le Mans, France
| |
Collapse
|
11
|
Bianchini F, Weiderpass E, Kyrtopoulos S, Souliotis VL, Henry-Amar M, Wild CP, Boffetta P. Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers 2008; 1:226-31. [DOI: 10.3109/13547509609079362] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
12
|
Mounier N, Heutte N, Flechtner H, Mellink AM, Brice P, Gaillard I, Traulle C, Ferme C, Eghbali H, Henry-Amar M. Quality of life in early stage Hodgkin lymphoma (HL) patients from the EORTC-GELA H8 Trial (20931): A post-treatment longitudinal study of 1,015 patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Klein D, Mercier M, Lemoisson E, Vinsu C, Danzon A, Dalstein V, Pozet A, Guizard AV, Henry-Amar M, Velten M. Qualité de vie à long terme après un cancer du sein en France. Rev Epidemiol Sante Publique 2008. [DOI: 10.1016/j.respe.2008.03.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
14
|
Joly F, Petit T, Pautier P, Guardiola E, Mayer F, Chevalier-Place A, Delva R, Sevin E, Henry-Amar M, Bourgeois H. Weekly association of gemcitabine and topotecan in early recurrent ovarian cancer patients: A French multicenter phase II study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16016 Background: A weekly association of gemcitabine and topotecan was tested with the aim of evaluating its efficacy and tolerance in patients recurring after first line platinum and taxane-based chemotherapy. Methods: From December 2004 to April 2006, 77 patients whose disease has progressed within 12 months (time-free interval, TFI) after first line chemotherapy were enrolled in a multicenter phase II study. Primary endpoint was overall response rate (ORR). Gemcitabine (1000 mg/m2) and topotecan (2.5 mg/m2) were given day 1, 8 and 15 (q 28 d) for 6 to 9 cycles. Tumor response was assessed according to RECIST or Rustin criteria. Clinical response was assessed using symptoms improvement in responders and patients with stable disease. Follow-up was updated December 2006. Results: Initial characteristics were: median age 63 years (38 to 80), WHO PS 0–1 93%, serous histology 85%, TFI < 6 months 45%, measurable disease 71%. Four cycles (1 to 8) were administered in average. The only major toxicity was neutropenia (Grade 3 and 4 in 17% and 6% of patients) with one febrile neutropenia; one toxic death (pneumopathy) was observed. 34% of cycles were incomplete (d8 and/or d15 not administered) because of grade 1–2 thrombopenia or grade 1–4 neutropenia. Lenograstim and erythropoietin were administered in 14% and 34% of patients, respectively. Sixty-six (86%) patients were evaluable for response (2 cycles administered). The ORR was 14% (CR=3%, PR=11%); there were 53% of stable disease. ORR was 7% and 20% in patients with TFI < 6 months and = 6 months, respectively. Symptoms were improved in 18 (64%) of 28 patients and pain in 11 (39%) of 28 patients. Median event-free survival time was 3.7 months. Median overall survival time was 12.3 months (7.5 and 15.6 months in patients with TFI < 6 months and = 6 months, respectively; p=0.0244). Conclusions: In resistant/refractory ovarian cancer, weekly gemcitabine and topotecan is associated with low objective response rate but with a high proportion of stable disease and symptoms control leading to acceptable quality of life. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Joly
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - T. Petit
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - P. Pautier
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - E. Guardiola
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - F. Mayer
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - A. Chevalier-Place
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - R. Delva
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - E. Sevin
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - M. Henry-Amar
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| | - H. Bourgeois
- Centre Francois Baclesse, Caen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; CHU Jean Minjoz, Besançon, France; Centre Georges-Francois Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Paul Papin, Angers, France; Centre Hospitalier, Amboise, France
| |
Collapse
|
15
|
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Fermé C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17:1749-60. [PMID: 16984979 DOI: 10.1093/annonc/mdl302] [Citation(s) in RCA: 151] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial. PATIENTS AND METHODS We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto's method. RESULTS Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62-0.98 and P = 0.03). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00-1.89 and P = 0.05). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR (P = 0.28) although more breast cancers occurred with EF-RT (P = 0.04 and OR = 3.25). CONCLUSIONS Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies.
Collapse
Affiliation(s)
- J Franklin
- German Hodgkin Study Group, University of Cologne, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Heutte N, Mounier N, Flechtner H, Mellink AM, Meerwaldt JH, Fermé C, Eghbali H, Henry-Amar M. Results of a longitudinal survey on quality of life (QoL) in 935 patients with supradiaphragmatic early stage Hodgkin lymphoma (HL) enrolled in the EORTC-GELA H8 trial (# 20931). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8582 Background: To study the change in posttreatment QoL and fatigue in patients with supradiaphragmatic early stage HL. Methods: QoL assessment was made using the EORTC QLQ-C30 core questionnaire and fatigue was assessed using the MFI-20 questionnaire. Questionnaires were given immediately after treatment completion and every 6 months thereafter for at least a period of 5 years. Mixed models (Med Decis Making 2003;3:54–66) were used to assess statistically reliable changes of the variables tested with time because they allow unequal number of assessments per patients. Variables tested were the 7 functioning scales and the fatigue scale of the QLQ-C30 questionnaire, the 5 MFI-20 fatigue scales, and time using 6 time periods: 0–6, 7–14, 15–21, 22–32, 33–47, ≥48 months following the end of treatment. The impact of gender, age (<30, 30–49, ≥50 years), treatment (mantle-field irradiation, subtotal nodal irradiation (STNI), 3, 4 or 6 MOPP-ABV and involved-field irradiation or 4 MOPP-ABV and STNI) and treatment-related acute grade 3–4 toxicity was also tested. Patients were censored at relapse when occurred. Results: Of the 1577 patients enrolled in the trial (1993–1998), 935 (59%, median follow-up 7 years) participated for a total of 3,227 assessments. Main clinical characteristics did not differ between patients with missing QoL forms and those with complete data. There were no significant differences in disease-free survival between treatment arms. Significant (P<0.001) improvement with time was observed for all QoL and fatigue variables tested. Overall, young age and male sex significantly (P<0.01) correlated with improvement in all QLQ-C30 dimensions except cognitive functioning. Treatment duration ≥6 months had a significant (P<0.005) negative impact on global QoL. Age≥30 years and treatment duration ≥2 months negatively (P<0.05) influenced MFI-20 variable changes. Previous toxicity and age ≥30 years altered mental fatigue and motivation. Conclusions: QoL data from the reintegration process of patients into normal life during the first follow-up years show substantial limitations. The impact of treatment is limited. Fatigue remains of great concern in these patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Heutte
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - N. Mounier
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - H. Flechtner
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - A. M. Mellink
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - J. H. Meerwaldt
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - C. Fermé
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - H. Eghbali
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| | - M. Henry-Amar
- EORTC Lymphoma Group-Gela; LMNO, Université de Caen Basse-Normandie, Caen, France; Hôpital Saint-Louis, Paris, France; University Hospital, Köln, Germany; University Medical Centre, Utrecht, The Netherlands; Medisch Spectrum Twente, Enschede, The Netherlands; Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France
| |
Collapse
|
17
|
Andrieux A, Switsers O, Chajari MH, Jacob JH, Delozier T, Gervais R, Allouache N, Laurençon V, Henry-Amar M, Bardet S. Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera. Q J Nucl Med Mol Imaging 2006; 50:68-77. [PMID: 16557206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
AIM Positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) can be performed using a dedicated PET scanner (PET-I) or a dual-head coincidence gamma camera (CGC-I). The aim of this study was to comparatively assess the impact of PET-I and CGC-I on clinical management in cancer patients. METHODS From November 2000 to November 2002, PET-I and CGC-I were performed at an interval of 2 days in 151 patients with colorectal cancer (n=40), breast cancer (n=28), thyroid cancer (n=23), lung tumors (n=22), germ cell tumors (n=14), unknown primary cancer (n=7) and other cancers (n=17). PET-I and CGC-I were interpreted independently with knowledge of conventional imaging (CI). In June 2003, theoretical management, e.g. treatment modality/ies and treatment intent (curative or palliative), after CI, PET-I and CGC-I were stated during multidisciplinary sessions and were a posteriori considered as appropriate or inappropriate using pathological and follow-up data. RESULTS The theoretical management proposed after PET-I and after CGC-I was similar in 112/151 (74%; 95% CI: 66-81%) patients. In 125 assessable patients, theoretical management after PET-I was appropriate in 86% (95% CI: 79-92%), significantly higher (P=0.0033) than after CGC-I (70%; 95% CI: 62-78%). Both proportions were also higher than after CI (46%; 95% CI: 37-56%), (P<0.0001). A similar trend for higher proportions of appropriate management after PET-I than after CGC-I was observed for each tumor localization. CONCLUSIONS The clinical impact of PET-I is superior to that of CGC-I in a large series of cancer patients. Although CGC-I could be considered as an acceptable alternative, PET-I remains the standard and should preferably equip nuclear medicine departments.
Collapse
Affiliation(s)
- A Andrieux
- Department of Nuclear Medicine, François Baclesse Center, Caen, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
de Jong D, Bosq J, MacLennan KA, Diebold J, Audouin J, Chasle J, Mandard AM, Marnay J, Henry-Amar M. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Ann Oncol 2006; 17:141-5. [PMID: 16284059 DOI: 10.1093/annonc/mdj037] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND To investigate the proportion, clinical characteristics and outcome of lymphocyte-rich classical Hodgkin lymphoma (LRCHL) in relation to nodular lymphocyte predominant HL (NLPHL) and classical HL (cHL). PATIENTS AND METHODS A series of 2743 HL patients of all stages enrolled into three EORTC trials (H7, H8, H34) conducted between 1988 and 2000 and forming an unbiased series of HL patients was studied. RESULTS Detailed histological classification after panel review was available in 96% of the cases to allow selection of all cases with features potentially compatible with the WHO-definition of LRCHL for this study. Cases with dominance of lymphocytic infiltrate and relative paucity of eosinophils and fibrosis could be selected for re-classification. Twenty-one (0.8%) LRCHL cases were identified of which three were originally classified as NLPHL, seven as nodular sclerosis HL (NSHL) and 11 as mixed cellularity (MCHL), indicating that LRCHL is a rare disease. CONCLUSIONS Clinical evaluation of the unselected series of patients (n = 2743) showed that LRCHL and NLPHL cases more often presented with favorable features. Clinical outcome adjusted on ab initio patient prognosis did not differ between the three histological entities. These results strongly suggest that LRCHL corresponds to an early stage in the spectrum of cHL rather than a biologically different disease entity.
Collapse
Affiliation(s)
- D de Jong
- The Netherlands Cancer Institute, Amsterdam, the Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Chinet-Charrot P, Joly F, Bourgeois H, Lortholary A, Leduc B, Priou F, Cumin I, Sevin E, Hamond K, Henry-Amar M. Association of pegylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: A multicenter phase II trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Chinet-Charrot
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - F. Joly
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - H. Bourgeois
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - A. Lortholary
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - B. Leduc
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - F. Priou
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - I. Cumin
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - E. Sevin
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - K. Hamond
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| | - M. Henry-Amar
- Ctr Henri Becquerel, Rouen, France; Ctr François Baclesse, Caen, France; Ctr Hospitalo-universitaire, Tours, France; Ctr Paul Papin, Angers, France; Ctr Hospitalier, Brives, France; Ctr Hospitalier, La Roche sur Yon, France; Ctr Hospitalier, Lorient, France
| |
Collapse
|
20
|
Noordijk EM, Thomas J, Fermé C, van ’t Veer MB, Brice P, Diviné M, Morschhauser F, Carde P, Eghbali H, Henry-Amar M. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6505] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. M. Noordijk
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - J. Thomas
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - C. Fermé
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. B. van ’t Veer
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - P. Brice
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. Diviné
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - F. Morschhauser
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - P. Carde
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - H. Eghbali
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. Henry-Amar
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| |
Collapse
|
21
|
Gervais R, Ducolone A, Lechevalier T, Legroumellec A, Lemarie E, Quoix E, Le Pechoux C, Bardet E, Henry-Amar M, Douillard JY. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)]: Final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7016] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Gervais
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - A. Ducolone
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - T. Lechevalier
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - A. Legroumellec
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Lemarie
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Quoix
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - C. Le Pechoux
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Bardet
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - M. Henry-Amar
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - J.-Y. Douillard
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| |
Collapse
|
22
|
Czernichow P, Gehanno J, Carli M, Henry-Amar M, Van Elslande J, Bohu M, Peau M, Chastan S. P3-3 Investigation d’une suspicion d’agrégat de leucémie dans la zone de gaillon (Eure). Rev Epidemiol Sante Publique 2004. [DOI: 10.1016/s0398-7620(04)99241-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
23
|
Joly F, Tchen N, Chevreau C, Henry-Amar M, Priou F, Chinet-Charrot P, Rolland F, Droz JP, Journet V, Culine S. Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Joly
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - N. Tchen
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - C. Chevreau
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - M. Henry-Amar
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - F. Priou
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - P. Chinet-Charrot
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - F. Rolland
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - J.-P. Droz
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - V. Journet
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| | - S. Culine
- Centre François Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier, La Roche-sur-Yon, France; Centre Henri Becquerel, Rouen, France; Centre René Gauducheau, Nantes, France; Centre Léon Bérard, Lyon, France; Centre Val d'Aurelle, Montpellier, France
| |
Collapse
|
24
|
Lebailly P, Devaux A, Pottier D, De Meo M, Andre V, Baldi I, Severin F, Bernaud J, Durand B, Henry-Amar M, Gauduchon P. Urine mutagenicity and lymphocyte DNA damage in fruit growers occupationally exposed to the fungicide captan. Occup Environ Med 2003; 60:910-7. [PMID: 14634181 PMCID: PMC1740442 DOI: 10.1136/oem.60.12.910] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIMS To determine haematological parameters, urine mutagenicity (on three Salmonella typhimurium strains), and DNA damage (using the comet assay) in mononuclear leucocytes of farmers before and after a one-day spraying period of pear and apple trees with the fungicide captan in usual conditions. METHODS Fruit growers were exposed to captan during the 1998 (n = 12) and/or the 2000 spraying seasons (n = 17). Biological samples were collected on the morning of the day of spraying (S1), the evening after spraying (S2), and the morning of the day after (S3). The UK Predictive Operator Exposure Model (UK-POEM) was used to quantify pesticide exposure intensity. RESULTS No effect was observed on haematological parameters for these two spraying seasons. Proportions of mutagenic urine samples did not significantly differ between S1 and S2/S3 sampling points. In contrast with strains TA97a and YG1041 mainly sensitive to frameshift mutations, a positive trend was observed between the difference (S3-S1) of mutagenic power on strain TA102 detecting base-pair mutations and the exposure predicted value given by UK-POEM, mainly due to parameters related to protective clothing. No significant variations in DNA damage levels were observed between S1 and S3, nor were correlations observed with parameters of pesticide exposure. CONCLUSIONS A one-day spraying period with captan and other pesticides does not significantly induce DNA damages in mononuclear leucocytes. In contrast, an inefficient protective clothing could correlate with an increase in urine mutagenicity as assessed by the TA102 tester strain.
Collapse
Affiliation(s)
- P Lebailly
- GRECAN (EA-1772), Université de Caen, 14076 CAEN Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Brune D, Lesaunier F, Benabid D, M'vondo M, Henry-Amar M. 874 Ir192 conformal brachytherapy and external beam radiation (EBR-CU.ir192) with or without hormonotherapy for locally advanced prostate adenocarcinoma: the centre françois baclesse experience. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90900-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
26
|
Bardet S, Rohmer V, Boux de Casson F, Coffin C, Ronci N, Sabatier JP, Lecomte P, Audran M, Henry-Amar M, Tabarin A. [Bone mineral density and biological markers of bone repair in patients with adrenal incidentaloma: effect of subclinical hypercortisolism]. Rev Med Interne 2002; 23:508-17. [PMID: 12108175 DOI: 10.1016/s0248-8663(02)00606-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Some adrenal incidentalomas produce cortisol in mild excess ('subclinical' Cushing's adenomas) and can potentially induce osteopenia. Their diagnosis is usually based on exclusive tumour uptake on adrenal scintigraphy using 131I-6 beta-methyl-iodo-19-norcholesterol and on inadequate cortisol response to dexamethasone (DXM) suppression tests. The aims of the present study were to evaluate bone mineral density (BMD) and metabolic markers of bone turnover in patients with incidentalomas and to test the effect of mild hypercortisolism on bone parameters. METHODS Thirty-five patients (13 men, 22 postmenopausal women, 49-76 years) with unilateral incidentaloma were studied. BMD was measured by dual X-ray absorptiometry. Two biochemical markers of bone formation, serum osteocalcin (BGP) and bone alkaline phosphatase (bALP), and two markers of bone resorption, urinary free deoxypyridinoline (D-Pyr) and urinary carboxy-telopeptide of bone type 1 collagen (CTX), were measured by radioimmunoassay. D-Pyr and CTX were corrected for creatinine excretion. RESULTS Median values of lumbar and femoral T-score were -1.125 and -0.920, respectively, whereas corresponding Z-score values where normal (0.105 and 0.120, respectively). Thirty-nine percent of patients had low serum BGP values and 3% had low bALP values; 16% showed elevated D-Pyr/creatinine values and 23% increased CTX/creatinine values. Patients both with suppression of the contralateral adrenal on scintigraphy and with an inadequate cortisol response to 1 mg DXM (> 50 nmol/L) (n = 14) presented a lower femoral T-score (P < 0.02) and, to a lesser extent, a lower femoral Z-score (P = 0.11) than other patients (n = 21). The proportion of increased values of CTX/creatinine (42% versus 11%, P = 0.08) also tended to be higher in the first than in the second group of patients. These two groups of patients were similar in terms of age, but tumour size was larger (P < 0.04) and plasma ACTH value was lower (P < 0.02) in patients with scintigraphic and endocrine abnormalities. CONCLUSION Subclinical hypercortisolism defined on the basis of scintigraphic and hormonal criteria seems to contribute to bone loss in patients with adrenal incidentaloma. As other possible side effects of mild hypercortisolism, these findings have to be taken into account in the therapeutic management of these patients.
Collapse
Affiliation(s)
- S Bardet
- Service de médecine nucléaire, centre François-Baclesse, route de Lion-sur-Mer, 14076 Caen, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke MV, Henry-Amar M, Carde P. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002; 38 Suppl 4:S107-13. [PMID: 11858975 DOI: 10.1016/s0959-8049(01)00446-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
From 1964 onwards, the EORTC Lymphoma Group has conducted seven consecutive randomised phase 3 trials on early stage Hodgkin's lymphoma aiming at increasing efficacy, while decreasing short- and long-term toxicity. Staging laparotomy is definitely abandoned and replaced by identification of prognostic subgroups based on pretreatment clinical characteristics. Event-free and overall survival significantly improved from about 50 and then 70%, in the early years, to over 80 and then 90% more recently. Radiotherapy fields have become more restricted, whereas chemotherapy has become standard. Longitudinal quality-of-life assessment has become an integral part of our studies. In advanced stages, overall outcome has improved as well with 6-year survival rates of over 80%. In aggressive types of NHL, the second generation chemotherapy schedule CHVmP-BV was superior to CHVmP. We could not show any advantage for intensification of upfront treatment with autologous stem cell transplantation.
Collapse
Affiliation(s)
- J Raemaekers
- Deptartment of Hematology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Joly F, Héron JF, Kalusinski L, Bottet P, Brune D, Allouache N, Macé-Lesec'h J, Couëtte JE, Pény J, Henry-Amar M. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol 2002; 20:73-80. [PMID: 11773156 DOI: 10.1200/jco.2002.20.1.73] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate quality of life and social problems in long-term survivors of testicular cancer. PATIENTS AND METHODS In 1998, 71 testicular cancer survivors (cases) identified from the Calvados General Tumor Registry were enrolled onto a case-control study. One hundred nineteen healthy control subjects (controls), matched by age and location of residence, were selected at random from electoral rolls. Three self-administered questionnaires were used: two health-related quality-of-life questionnaires (Short Form-36 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 core questionnaires) and one life situation questionnaire. Specific questions concerning sexuality were also added. RESULTS With a mean follow-up of 11 years, health-related quality-of-life scores did not differ significantly between cases and controls, nor did general symptom scores. Psychosocial problems were reported equally by cases and controls. Cases reported more modification of sexual life (P =.04) with decreased sexual enjoyment (P <.01), decreased desire (P =.02), and infertility (P <.01). Cases did not report more divorce than controls; they reported fewer changes in relationships with friends (P =.03). Although a similar proportion of cases and controls were at work, cases expressed less ambitious professional plans (P =.002). Cases had greater difficulty in borrowing from banks (P <.001). CONCLUSION French long-term survivors of testicular cancer do not express more impairment of health-related quality of life or familial or professional life in comparison with healthy men. They did have more sexual life problems and found difficulty in borrowing from banks. This information should be used by practitioners to help their patients cope with their disease and return to normal life.
Collapse
Affiliation(s)
- F Joly
- Groupe Régional d'Etudes sur le Cancer (EA-1772), Centre François Baclesse, University of Caen-Basse, Normandie, 14076 Caen Cedex 5, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Aleman B, Raemaekers J, Henry-Amar M, Pinna A, Girinsky T, Lybeert M, Meerwaldt J, Thomas J, Tirelli U, Mandard A. Involved-field radiotherapy in patients with stage III/IV Hodgkin’s lymphoma: first results of the randomised EORTC trial # 20884. Int J Radiat Oncol Biol Phys 2001. [DOI: 10.1016/s0360-3016(01)01827-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Ferme C, Cosset JM, Fervers B, Sebban C, Cutuli B, Henry-Amar M, Stines J, Giammarile F, Bey P, Carella AM, Philip T. Hodgkins disease. Br J Cancer 2001; 84 Suppl 2:55-60. [PMID: 11355971 PMCID: PMC2408841 DOI: 10.1054/bjoc.2000.1765] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- C Ferme
- Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Durand N, Crémilleux B, Henry-Amar M. Discovering Associations in Clinical Data: Application to Search for Prognostic Factors in Hodgkin’s Disease. Artif Intell Med 2001. [DOI: 10.1007/3-540-48229-6_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Mandard AM, Denoux Y, Herlin P, Duigou F, van De Vijver MJ, Clahsen PC, van Den Broek L, Sahmoud TM, Henry-Amar M, van De Velde CJ. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer 2000; 89:1748-57. [PMID: 11042570 DOI: 10.1002/1097-0142(20001015)89:8<1748::aid-cncr15>3.0.co;2-e] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The clinical relevance of DNA image cytometry (ICM) and flow cytometry (FCM) remains under investigation in breast carcinoma. The objective of the current work was to study the prognostic value of DNA ICM and FCM in a series of patients randomized in a control trial. A multivariate analysis has been performed including other factors still under investigation such as Ki-67 index, mitotic count, microvessel density, and P53 and Bcl-2 expression. METHODS Two hundred and eighty-one patients were randomized in the European Organization for Research and Treatment of Cancer 10854 trial comparing surgery followed by one course of perioperative chemotherapy versus surgery alone. Tumor parameters studied were pT, multicentricity, tumor grading according to modified Scarff-Bloom-Richardson, estrogen receptors, mitotic count per 1.7 mm(2), MIB-1, and BCL-2 scores, microvessel density, and p53 expression. ICM DNA parameters studied from paraffin embedded specimens, were DNA ploidy, proliferative index, 2c deviation index, malignancy grade, and Auer-Baldetorp typing. FCM DNA parameters analyzed on the same samples were ploidy and S-phase fraction statistics. The influence of tumor parameters, and DNA parameters on overall survival (OS), disease free survival (DFS), and metastasis-free survival (MFS) was evaluated using the Cox model. Median follow-up was 82 months. RESULTS For OS, the prognostic parameters retained were pathologic tumor size (pT) and mitotic index (MI). Overall survival was 94% and 68% for tumors pT1/MI less than 10 and pT2-3 MI greater than or equal to 10, respectively. For DFS, age, multicentricity, and grading according to modified Scarff and Bloom were predicting factors with the same relative risk. Disease free survival was 96%, 78% and 68% respectively, when 1, 2, or 3 of those factors were present. For MFS, the only retained predicting factor was MI. MFS was 97% and 73% when MI was less than 10 and MI was greater than or equal to 10, respectively. CONCLUSIONS Evaluation of proliferative compartment was the most important predicting factor for OS and MFS in the current series of premenopausal lymph node negative patients with breast invasive carcinoma. When working on paraffin embedded tissue, the best way of assessing it was MI count. ICM DNA analysis results were not selected in multivariate analysis. DNA analysis by FCM should be considered as an unsuitable technique when working on paraffin embedded tissue.
Collapse
Affiliation(s)
- A M Mandard
- Department of Pathology, Centre François Baclesse, Caen, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Joly F, Espié M, Marty M, Héron JF, Henry-Amar M. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 2000; 83:577-82. [PMID: 10944595 PMCID: PMC2363517 DOI: 10.1054/bjoc.2000.1337] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Our purpose was to evaluate the late physical and psychosocial difficulties of premenpausal patients treated for a localized breast cancer and to weigh the impact of chemotherapy on long-term quality of life. Two self-administered questionnaires, the EORTC core QLQ-C30 and the breast module (BR23) were mailed to 179 premenopausal node-negative women continuously disease-free, previously enrolled in a trial testing the efficacy of adjuvant CMF chemotherapy (Espié et al, 1997). The core questionnaire evaluates the physical, role, emotional, cognitive and social functioning and global health status. The breast module includes four functional scales: body image, sexual functioning, sexual enjoyment and future perspective. It also includes symptom scales such as arm or breast symptoms. Some specific professional and social states were added. 119 (68%) patients (mean age 54 years, range 30-69) participated. Mean follow-up time since diagnosis was 9.6 years (4-16). 68% had conservative and 32% radical surgery (with reconstructive surgery in 50%). CMF was given to 77 (65%) patients. Irradiation was administered in 75% of patients irrespective of adjuvant therapy. QLQ-C30 scale scores were similar in patients who had or had not received chemotherapy. Disturbance in body image, sex life and breast symptoms did not differ between patients who had or had not received adjuvant CMF. No major socioprofessional difficulties were reported except problems in borrowing from banks not related to past chemotherapy. With long follow-up, most premenopausal women treated for a localized breast cancer cope with the disease and its treatments. Adjuvant CMF chemotherapy does not appear to impair quality of life nor social and professional life in these patients.
Collapse
Affiliation(s)
- F Joly
- Service de Recherche Clinique, Service d'Oncologie, Centre François Baclesse, Route de Lion-sur-Mer, Caen cedex 5, 14076, France
| | | | | | | | | |
Collapse
|
34
|
Delcambre C, Reman O, Henry-Amar M, Peny AM, Macro M, Cheze S, Génot JY, Tanguy A, Switsers O, Van HL, Couëtte JE, Leporrier M, Bardet S. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27:176-84. [PMID: 10755723 DOI: 10.1007/s002590050024] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The clinical impact of gallium-67 scintigraphy before and after therapy for lymphoma remains controversial. The aims of this study were: (1) to compare the staging of lymphoma by 67Ga scintigraphy only with staging by clinical examination and conventional imaging (CI), and (2) to analyse the clinical relevance of both 67Ga imaging and CI after treatment. From March 1995 to November 1998, 86 67Ga scintigraphy studies were performed in 62 patients with Hodgkin's disease (n=52) or non-Hodgkin's lymphoma (n=10). 67Ga scintigraphy was performed at diagnosis (n=44) or after therapy (n=42) using 185-220 MBq 67Ga citrate and planar and single-photon emission tomography (SPET) studies. Treatment comprised radiotherapy, chemotherapy or combined modalities. CI included plain chest radiography, computed tomography (CT) of the chest and abdomen/pelvis, ultrasound of the abdomen, lymphography, bone marrow biopsy and, when necessary, magnetic resonance imaging (MRI) and bone scintigraphy. For individual suspected sites of disease before treatment, complete agreement between clinical examination and CI on the one hand and 67Ga scintigraphy on the other hand was observed in 25/44 patients (57%; 95% confidence interval 41%-72%). Clinical examination and CI showed more sites than did 67Ga scintigraphy in 12/44 patients (27%) and 67Ga imaging demonstrated more sites than CI in 6/44 patients (11%). The clinical stage of the disease as assessed using 67Ga scintigraphy only was in agreement with that using all diagnostic procedures in 34/44 patients (77%; 95% confidence interval 62%-89%). Compared with CI staging, 67Ga scintigraphy downstaged seven patients (16%) and upstaged three (7%). 67Ga scintigraphy downstaged mainly because of the limited value of the technique below the diaphragm and upstaged owing to the good sensitivity in the lung. After therapy, both CI and 67Ga scintigraphy were normal in 11 patients. All but one of these patients were in complete remission after a median follow-up of 31 months. In contrast, radiological residual mass was observed in 31/42 patients. 67Ga imaging was normal in 22/31 (71%); 17 of these 22 patients, including nine with a large residual mass (> or =2 cm), were in complete remission after a median follow-up of 32 months, while four suffered relapses 8-45 months later. The cause of death remained unknown in one patient. 67Ga scintigraphy showed abnormal uptake in 9 of the 31 patients with a large residual mass. Active disease was demonstrated in eight patients and one patient was in complete remission 30 months thereafter. Our data show that 67Ga imaging cannot replace CI in initial staging but can demonstrate additional individual sites of disease in more than 10% of patients and can lead to clinical upstaging with potential prognostic and therapeutic consequences. After therapy, 67Ga scintigraphy has a clinical impact when radiological abnormalities persist because it can either avoid unnecessary complementary treatment or confirm the need to change treatment modalities.
Collapse
Affiliation(s)
- C Delcambre
- Service de Médecine Nucléaire, Centre François Baclesse, Caen, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Roberge C, Tran M, Massoud C, Poirée B, Duval N, Damecour E, Frout D, Malvy D, Joly F, Lebailly P, Henry-Amar M. Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. Br J Cancer 2000; 82:263-9. [PMID: 10646875 PMCID: PMC2363272 DOI: 10.1054/bjoc.1999.0913] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
A prospective study was conducted to evaluate the impact of home enteral tube feeding on quality of life in 39 consecutive patients treated for head and neck or oesophageal cancer at the Centre François Baclesse in Caen, France. Patients were taken as their own controls. Quality of life was evaluated using the EORTC QLQ-C30 core questionnaire, and the EORTC H&N35 and OES24 specific questionnaires. The feeding technique tolerance was evaluated using a questionnaire specifically developed for this study. Two evaluations were made, the first a week after hospital discharge (n = 39) and the second 3 weeks later (n = 30). Overall, the global health status/quality of life scale score slightly improved; among symptoms, scale scores that significantly improved (P < 0.05) concerned constipation, coughing, social functioning and body image/sexuality. The physical feeding technique tolerance was acceptable while the technique was psychologically less tolerated with two-thirds of the patients longing to have the tube removed. One third of the patients was also uncomfortable about their body image. Home enteral tube feeding was responsible for not visiting family or close relations in 15% of patients, and not going out in public in 23%. We conclude that home enteral tube feeding is a physically well accepted technique although a substantial proportion of patients may experience psychosocial distress.
Collapse
Affiliation(s)
- C Roberge
- Service de Recherche Clinique, Centre François Baclesse, Caen, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Fermé C, Cosset JM, Fervers B, Sebban C, Cutuli B, Henry-Amar M, Stines J, Giammarile F, Bey P, Carella AM, Philip T. [Standards, options and recommendations for the management of adult patients with Hodgkin disease. Standards, Options and Recommendations (SOR) in Cancerology. Groupe d'Etude des Lymphomes de l'Adulte]]. Presse Med 1999; 28:2233-45. [PMID: 10636018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
|
37
|
Abstract
The role of radiotherapy in limited stage Hodgkin's disease (HD) has been gradually changing in the past few decades, resulting in the almost complete disappearance of exclusive irradiation treatment. In reality, exclusive radiotherapy yielded satisfactory results in terms of long-term survival, but in 1999 it was becoming impossible not to take into account the late mortality rates observed in all large cohorts of HD patients. This increased mortality rate has been shown to be related to 1) cardiac toxicity of irradiation, and 2) secondary radiation-induced solid tumors. Thus, the search for efficient but less toxic new strategies can no longer be avoided. For clinically staged, limited HD, precisely defined according to specific prognostic factors, the association of chemotherapy and radiotherapy appears more and more as a standard, and with this therapeutic burden comes parallel efforts for its alleviation. The Previous Radiotherapy experience has shown that, after a chemotherapy-induced complete remission, irradiation of only the initially involved areas was enough. Ongoing trials are now exploring the possibility of a dose de-escalation, from the conventional 36 Gy to 20 Gy (as for children HD), and to maybe 0 Gy (no radiotherapy at all). In parallel, deescalation in the number of chemotherapy cycles is also being investigated. For unfavorable cases, the problem is slightly different, as a higher percentage of cases still appears to be refractory to treatment in this subgroup. Thus, while chemo-radiotherapy has clearly became the standard strategy, efforts are essentially being devoted to identify new--and hopefully more efficient--chemotherapy schemes. In Europe, most of these pending questions will be addressed in the recently initiated trials of the EORTC/GELA and of the GHSG (German Hodgkin Study Group), with the aim of offering to patients treatment which could be at least as efficient as the present schedules, and less toxic in the long term.
Collapse
|
38
|
Tichelli A, Socié G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H, McCann S, Hows J, Ljungman P, Marin P, Raghavachar A, Locasciulli A, Gratwohl A, Bacigalupo A. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 1999; 130:193-201. [PMID: 10049197 DOI: 10.7326/0003-4819-130-3-199902020-00004] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Immunosuppressive therapy has been used for successful treatment of severe aplastic anemia, but little information is available on outcome in older patients. OBJECTIVE To evaluate outcome in patients older than 50 years of age who received immunosuppressive therapy for aplastic anemia. DESIGN Retrospective cohort study. SETTING 56 centers of the European Group for Blood and Marrow Transplantation (EBMT). PATIENTS 810 patients with aplastic anemia reported between 1974 and 1997. Patients were evaluated according to age group: 60 years of age or older (n = 127), 50 to 59 years of age (n = 115), and 20 to 49 years of age (n = 568; reference group). INTERVENTION Antilymphocyte globulin, cyclosporine, or both. MEASUREMENTS Survival, cause of death, response to treatment, relapse rate, and risk for late complications were analyzed in all patients and by age group. RESULTS The 5-year survival rate was 57% (95% CI, 46% to 66%) in patients 50 to 59 years of age and 50% (CI, 39% to 60%) in patients 60 years of age or older compared with 72% (CI, 68% to 76%) in patients younger than 50 years of age (P < 0.001). Response to therapy, relapse rate, and risk for clonal complications were similar in all three age groups (P > 0.2). Age was significantly associated with an increased risk for death (relative risk compared with patients 20 to 49 years of age, 1.80 [CI, 1.29 to 2.52] for patients 50 to 59 years of age and 2.57 [CI, 1.87 to 3.53] for patients > or = 60 years of age), mainly because of bleeding or infection (P = 0.02). Response to immunosuppressive therapy in all patients at 12 months was 62% (CI, 58% to 66%); no difference was seen among the age groups in multivariate analysis (P > 0.2). Sixty-six of the 379 responding patients (17%) subsequently had relapse. The risk for clonal disorders at 10 years was 20% (CI, 15% to 27%). CONCLUSIONS Response to immunosuppression in aplastic anemia is independent of age, but treatment is associated with increased mortality in older patients.
Collapse
Affiliation(s)
- A Tichelli
- Department Zentrallabor, Kantonsspital Basel, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Flechtner H, Rüffer JU, Henry-Amar M, Mellink WA, Sieber M, Fermé C, Eghbali H, Josting A, Diehl V. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Ann Oncol 1999; 9 Suppl 5:S147-54. [PMID: 9926255 DOI: 10.1093/annonc/9.suppl_5.s147] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Previous reports from available trials have dealt with negative long-term sequelae in Hodgkin's disease (HD) survivors. There is, however, a lack of longitudinal data showing the correlation between outcome and various treatment-related variables and the process of re-adaptation into normal life after the end of treatment. In order to investigate the quality of life (QoL) of patients with HD in different dimensions during active treatment and follow-up and to identify longitudinal patterns of QoL dimensions during re-adaptation to normal life within the EORTC Lymphoma Cooperative Group and Groupe D'Etude des Lymphomes de L'Adulte (EORTC/GELA) and the German Hodgkin Study Group (GHSG), QoL assessment strategies were put into use over the last three to five years. Furthermore, the efforts aimed at obtaining cross-cultural comparisons between the participating countries and study groups (EORTC/GELA and GHSG). Within the randomised EORTC/GELA Trial 'H8' for clinical stage I-II HD which started in September 1993, patients receive a QoL questionnaire for completion at each follow-up visit during the first 10 years after the end of active therapy. The corresponding 'HD8' study of the GHSG employs the assessment of QoL during and after active treatment periods. Within both studies, the EORTC QLQ C30 is used for QoL assessment incorporated in the QLQ-S (quality of life questionnaire for survivors), which additionally addresses the aspects of fatigue/malaise, sexuality, specific side effects, and retrospective evaluation of treatment. In total the QLQ-S includes 45 questions on 14 functional, symptom, and fatigue scales, 15 additional single items, and 3 open questions. In addition to the longitudinal QoL assessment, the GHSG carried out cross-sectional QoL trials with all cured surviving patients from the past HD1-6 studies and a matched normal control sample employing the QLQ-S and the life situation questionnaire (LSQ), an instrument covering objective data from 45 domains of life. To date, within the trials H8 and HD8 over 3000 QoL questionnaires from more than 800 patients from ten countries are available for analysis. Replication of the psychometric properties of the scales revealed satisfactory results using factor analyses and reliability testing across languages for the QLQ-S. A feasibility analysis showed generally a good acceptance of the questionnaire by the patients and physicians. QoL assessment within international multicentre trials in HD proved feasible within the two differently organised study groups of EORTC/GELA and GHSG. The use of subjective QoL data (QLQ-S) together with objective data (LSQ) in a combined cross-sectional and longitudinal trial system will give the most comprehensive insight into the problems of the re-integration process into normal life after cure. This information will provide the basis for the development of remedies/help measures and possible modifications of treatment strategies. The current approach will be further developed in close collaboration between both trial groups, and next steps will include translation of the LSQ into other languages and adaptation to various cultural circumstances.
Collapse
Affiliation(s)
- H Flechtner
- Department of Child and Adolescent Psychiatry, University of Cologne, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. J Clin Oncol 1999; 17:222-9. [PMID: 10458237 DOI: 10.1200/jco.1999.17.1.222] [Citation(s) in RCA: 127] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the prognostic factors and outcome of first-line induction failure Hodgkin's disease patients who were treated with a salvage regimen of high-dose chemotherapy and autologous stem-cell transplantation, and to compare them with matched, conventionally treated patients. PATIENTS AND METHODS We retrospectively analyzed data relating to 86 Hodgkin's disease patients who underwent autologous stem-cell transplantation after failure of the first chemotherapy regimen, either because they did not enter a complete remission and experienced progression of disease less than 3 months after the end of their first-line treatment or because they showed evidence of disease progression during first-line therapy. Graft patients were matched with 258 conventionally treated patients (three controls per case) for age, sex, clinical stage, B symptoms, and time at risk; patient data were obtained from international databases. RESULTS Among the 86 graft patients, the median age at diagnosis was 29 years (range, 14 to 57 years). Thirty-nine percent of patients had stage II disease, 23% had stage III disease, and 38% had stage IV disease. Seventy percent of the patients received chemotherapy and 30% received combined modality therapy; 60% of the patients received a seven- or eight-drug regimen. After this first-line treatment, 91% had disease progression and 9% had a brief partial response. Eighty patients received a second-line treatment; pretransplantation status was as follows: 24% of patients had a complete remission, 38% had a partial remission (PR), 14% had stable disease, and disease progression occurred in 24%. With a median follow-up of 22 months (range, 4 to 105 months) from diagnosis, the 5-year event-free survival and overall survival rates from transplantation were 25% and 35% (95% confidence intervals, 15 to 36 and 23 to 49), respectively. In multivariate analysis, the pretransplantation disease status after salvage therapy was the only significant prognostic factor for survival (PR: relative risk = 2.8, P = .017; progressive disease: relative risk (RR) = 5.26, P < .001). From diagnosis, the 6-year overall survival rates of the graft patients and 258 matched conventionally treated patients were 38% and 29%, respectively (P = .058). CONCLUSION Autologous stem-cell transplantation represents the best therapeutic option currently available for patients with primary induction failure and is associated with acceptable toxicity. Response to second-line treatment before high-dose chemotherapy is the only prognostic factor that can be correlated with survival.
Collapse
Affiliation(s)
- M André
- Hematology Institute, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Vigreux C, Poul JM, Deslandes E, Lebailly P, Godard T, Sichel F, Henry-Amar M, Gauduchon P. DNA damaging effects of pesticides measured by the single cell gel electrophoresis assay (comet assay) and the chromosomal aberration test, in CHOK1 cells. Mutat Res 1998; 419:79-90. [PMID: 9804902 DOI: 10.1016/s1383-5718(98)00126-0] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
One herbicide (isoproturon), two fungicides (carbendazim and chlorothalonil) and etoposide (an effective antitumor agent used as a positive control), were tested for their ability to induce cytotoxic and genotoxic effects in Chinese Hamster Ovary (CHOK1) cells. Etoposide induced DNA damage detectable both by the alkaline Single Cell Gel Electrophoresis (SCGE) assay and the chromosomal aberration (CA) test in absence of noticeable cytotoxicity. With the SCGE assay, a clear induction of DNA damage was observed for chlorothalonil within a 0.2 to 1 microM concentration range. In the CA test, chlorothalonil gave also positive results, inducing mainly chromosome breaks. In contrast, no DNA damage was observed with the SCGE assay for carbendazim and isoproturon. In the CA test, carbendazim induced only numerical aberrations in the concentration range of 25 microM to 100 microM, and isoproturon did not induce any significant increase in CA. In conclusion, chlorothalonil appears genotoxic in proliferative CHOK1 cells, and as expected, the aneugenic compound, carbendazim, did not induce DNA strand breaks in the SCGE assay.
Collapse
Affiliation(s)
- C Vigreux
- INSERM CJF 96-03 and EA 1772, Laboratoire de Cancérologie Expérimentale, Centre François Baclesse, Route de Lion-sur-mer, 14076, Caen Cedex 05, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Lebailly P, Vigreux C, Lechevrel C, Ledemeney D, Godard T, Sichel F, LeTalaër JY, Henry-Amar M, Gauduchon P. DNA damage in mononuclear leukocytes of farmers measured using the alkaline comet assay: discussion of critical parameters and evaluation of seasonal variations in relation to pesticide exposure. Cancer Epidemiol Biomarkers Prev 1998; 7:917-27. [PMID: 9796638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
The alkaline comet assay was used to quantify, using visual and image analyses, the level of DNA damage in mononuclear leukocytes of farmers who were occupationally exposed to pesticides. Hematological parameters were also measured on the same samples. Enrollment of farmers was based on handling of heavily used pesticides at particular periods during one spraying season. Forty-one blood samples from 29 different farmers were collected at the beginning of the season (n = 11) and at the intermediate (n = 14) and final (n = 16) periods of intense spraying activity. The mean numbers of lymphocytes and eosinophils were nonsignificantly higher in groups 3, 1, and 4 than they were in group 2. No individual characteristics significantly influenced the mean number of lymphocytes or eosinophils, and no correlation was observed between pesticide exposure-related parameters and hematological parameters. The level of DNA damage was significantly (P < 0.01) higher in groups 3, 1, and 4 than it was in group 2. In addition, DNA damage quantification was not significantly different among investigators or among slides. Prescription medicine, alcohol consumption, and age had no statistically significant effect on DNA damage level. Conversely, smoking (smokers versus non- and ex-smokers) significantly influenced DNA damage level (P < 0.0001). A significant (P < 0.05) negative correlation was detected between the number of days without pesticide spraying and DNA damage level, particularly among non- and ex-smokers. DNA damage detected by the alkaline comet assay seems to reflect ongoing exposure to genotoxic agents but not an accumulation of damage.
Collapse
Affiliation(s)
- P Lebailly
- Laboratoire de Cancérologie Expérimentale, Groupe Régional d'Etude sur le Cancer and Contrat Jeune Formation Institut National de la Santé et de la Recherche Médicale 96-03, Université de Caen, France
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lebailly P, Vigreux C, Lechevrel C, Ledemeney D, Godard T, Sichel F, LeTalaër JY, Henry-Amar M, Gauduchon P. DNA damage in mononuclear leukocytes of farmers measured using the alkaline comet assay: modifications of DNA damage levels after a one-day field spraying period with selected pesticides. Cancer Epidemiol Biomarkers Prev 1998; 7:929-40. [PMID: 9796639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
The alkaline comet assay was used to assess DNA damage in mononuclear leukocytes of farmers before and after a 1-day spraying period with selected pesticides under usual conditions. Two blood samples were collected, one in the morning of the day of spraying (S0) and the second in the morning of the day after (S1). Here, we assessed variations in DNA damage levels between these two sampling times. Four groups of farmers were formed, according to exposure to: (a) various fungicide-insecticide mixtures (including chlorothalonil; group 1, n = 8), (b) the herbicide isoproturon (group 2, n = 11), (c) fungicide triazoles (group 3, n = 14), and (d) a fungicide (chlorothalonil)-insecticide mixture (group 4, n = 8). An increase in DNA damage levels was observed at S1 for groups 1 and 4, who were exposed to similar pesticides. This increase was correlated with area sprayed between S0 and S1 and with the number of spraying tanks used over this 1-day period. No effect was observed on cell viability or on hematological parameters for these two groups. No statistically significant modification of DNA damage level was observed the day after spraying for groups 2 and 3, when each was observed as a whole. However, some farmers presented significantly more DNA damage after exposure, and others presented less damage. In these two groups, a significant decrease of neutrophils was observed at S1, and a decrease of red blood cells was observed in group 3. In parallel, a significant loss of lymphocyte viability was observed in these two groups. A 1-day spraying period seems to be sufficient to significantly modify DNA damage levels in mononuclear leukocytes, but the correlation of this change with pesticide-related exposure parameters depends on the kind of pesticide concerned.
Collapse
Affiliation(s)
- P Lebailly
- Laboratoire de Cancérologie Expérimentale, Groupe Regional d'Etude sur le Cancer and Contrat Jeune Formation-Institut National de la Santé et de la Recherche Medicale 96-03, Université de Caen, France
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Nedellec G, Attal M, Fermé C, Gisselbrecht C. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933-40. [PMID: 9731050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Autologous stem-cell transplantation has become a widely used therapy in Hodgkin's disease (HD). To appreciate the early and late risks associated with this procedure, its lethal toxicity and effects on the incidence of secondary cancers were studied. Data related to 467 French patients grafted from 1982 to 1995 for primary sensitive disease (PSD, 22%), primary refractory disease (PRD, 18%), first relapse (R1, 45%), or subsequent relapses (R2, 15%) were analyzed. Grafted patients (PSD, PRD, and R1; n = 393) were matched (3 controls for 1 case) on age, gender, clinical stage, B symptoms, and time at risk with 1179 conventionally treated patients issued from international databases. The proportional hazards (Cox) model was used to assess relative risks (RR). Among grafted patients, 8% died of toxicity related to the procedure, and 18 secondary cancers occurred leading to a 5-year cumulative incidence rate of 8.9%. In this series, risk factors for second cancer were age >/=40 years (RR = 3.73, P = .007) and the use of peripheral blood stem cells as source of graft (RR = 3.10, P = .03). Among grafted and matched ungrafted patients, risk factors for the development of secondary cancer were age >/=40 years (RR = 2.90, P < .001), relapse versus no relapse (RR = 5.22, P = .006), PRD versus other patients (RR = 3.86, P = .033), and grafted versus ungrafted patients (RR = 2.04, P = . 024). Solid tumors were more frequent in grafted than in ungrafted patients (RR = 5.19, P = .001) although the incidence of myelodysplasia and acute myeloid leukemia was similar in the two groups. We conclude that high-dose chemotherapy administered as first-line treatment or after relapse is associated with an acceptable toxic death rate. The risk of secondary myelodysplasia or acute myeloid leukemia is not significantly increased after autologous stem-cell transplantation for HD, whereas an increased risk of solid tumors exists. The peripheral blood stem-cell-associated risk of secondary cancer among grafted patients needs further investigations.
Collapse
Affiliation(s)
- M André
- Hematology Institute, Hôpital Saint-Louis, Paris, France; Clinical Research Unit and INSERM CJF 96-03/GRECAN, Centre Régional François Baclesse, Caen, France; Bone Marrow Transplantation Unit, Institut Paoli-Calmette, Marseille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Joly F, Brune D, Couette JE, Lesaunier F, Héron JF, Pény J, Henry-Amar M. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998; 9:751-7. [PMID: 9739442 DOI: 10.1023/a:1008276632623] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To evaluate late physical and psychosocial sequelae in patients treated with an association of external beam irradiation (EBI) and brachytherapy (BT) for localized prostate cancer. PATIENTS AND METHODS Seventy-one patients free of disease, treated at the Centre François Baclesse from 1988 to 1992, were enrolled in a case-control study. Seventy-one healthy controls, matched on age and residence, were selected at random from electoral rolls. Two self-administered questionnaires were mailed in January 1996. The French translation of the Nottingham Health Profile questionnaire and the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 core questionnaire were used to evaluate physical, role, emotional, cognitive and social functioning, global health status as well as energy and sleep disturbance. Specific problems related to prostate cancer were explored using the prostate specific module developed by the EORTC Genito-Urinary Tract Cancer Cooperative Group. Concordance between clinical complications reported by patients and those reported by physicians was also analyzed. RESULTS General health quality of life scale scores did not significantly differ between patients and controls, nor did general symptom scale scores. Furthermore, no more late psychosocial sequelae were reported by patients than by controls. No major digestive complications were observed among patients. However, statistical differences were observed concerning interest in sex (P = 0.016) and sexual activity (P < 0.001), urinary incontinence (P < 0.001) and cystitis (P = 0.01). Late subjective morbidity (dysuria, nocturia, urinary incontinence, pelvic pain) appraisal differed slightly between patients and physicians who generally underestimate its severity. While nocturia was reported more often by physicians than by patients (P = 0.0016), patients reported urinary incontinence and pelvic pain more often than physicians (P < 0.001 and P < 0.001, respectively). CONCLUSIONS The study demonstrates that survivors from localized prostate cancer treated with an association of BT and EBI have good global health status. Major problems that persist are sexual disorders, urinary incontinence and cystitis while digestive disorders were rare. This association could be an alternative to standard EBI in patients with localized prostate cancer. Whatever the treatment choice, patients should be involved in the therapeutic decision which should consider not only expected survival rate but also quality of life.
Collapse
Affiliation(s)
- F Joly
- Service de Recherche Clinique, Centre François Baclesse, Caen, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Henry-Amar M, Gisselbrecht C. [Late treatment related complications of Hodgkin's disease]. Rev Prat 1998; 48:1092-7. [PMID: 9781154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Patients cured of Hodgkin's disease are at high risk for developing late treatment-related complications. Radiation therapy is responsible for non malignant complications such as pulmonary, digestive, thyroid and cardiac toxicity. Chemotherapy is mainly responsible for pulmonary toxicity and gonadal dysfunction in females and in males, whatever the age at treatment. Hodgkin's disease therapy may also result in secondary malignancy which is considered the most serious complication. White the use of non leukaemogenic chemotherapy can limit the incidence of secondary leukaemia, that of secondary solid tumours is still increasing, being 15% after 20 years. Altogether, malignant and non malignant complications are still responsible for a non negligible overmortality.
Collapse
Affiliation(s)
- M Henry-Amar
- Service de recherche clinique Centre régional François-Baclesse, Caen
| | | |
Collapse
|
47
|
Brune D, Couette JE, Lesaunier F, Benabid D, Van Hoa LY, Mace-Lesech J, Henry-Amar M. Traitement de l'adénocarcinome prostatique par association radiothérapie-curiethéraphie. Cancer Radiother 1998. [DOI: 10.1016/s1278-3218(98)80010-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
|
49
|
Chaplain G, Grosclaude P, Arveux P, Raverdy N, Menegoz F, Henry-Amar M, Schaffer P, Daures JP, de Vathaire F. [Female genital and breast cancers in France: geographic distribution and estimation of incidence]. Bull Cancer 1997; 84:935-40. [PMID: 9435794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The aim of the study was to assess the incident number of female breast and genital tract cancers for the whole of France. The study focused on the 1983-1987 period and on 9.1% of the French population. The incident number of female breast and genital tract cancers was estimated for each site and for each of eight French administrative regions covered by a cancer registry qualified through the National Committee of Registries (Calvados, Côte-d'Or, Doubs, Hérault, Isère, Bas-Rhin, Somme, Tarn). Information on mortality rates was available at a regional level as well as at a nationwide level. The method estimated the national incidence rate modelizing the regional age-specific incidence rate as a function of corresponding mortality rate. Breast cancer was the leading site with 25,277 new cases per year while female genital tract cancers affected about 13,856 women. The cancer risk, estimated in using cumulative rate 0-74 years, was assessed at 7.1% for breast and at 1.2%, 1.4% and 1.1% for cervix uteri, corpus uteri and ovary respectively. Breast and genital tract cancers constituted 49% of the whole of cancers in women. Observed breast incidence rate was stable through French regions. There were pronounced contrasts in cervix uteri cancer risk, and some french regions displayed a high risk close to the observed European maxima. Interregional contrasts in risk of the other genital tract cancers were less striking. This study emphasized the importance of female breast and genital tract cancers for public health in France. The main aim of the French Cancer Registries Network is to provide a comprehensive description of cancer risk in France and to produce pertinent projection to 2005 horizon, combining the present data and the already accumulated 1988-1992 data.
Collapse
Affiliation(s)
- G Chaplain
- Registre des cancers gynécologiques de Côte-d'Or, Centre d'épidémiologie de population, Faculté de médecine, Dijon
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Joly F, Brune D, Couette J, Héron J, Henry-Amar M. Health-related quality of life and sequelae in patients treated with external beam irradiation (EBI) and brachytherapy for localized prostate cancer (LPC). Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)84525-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|